Filing Flows › Comparisons › CRMD vs HROW
CorMedix vs Harrow: CRMD and HROW compared
CorMedix is the larger company: $102M of revenue in its latest quarter (Q2 2026) against $99.3M for Harrow (Q3 2026). CorMedix is growing faster (+156% against +39% a year earlier). CorMedix is more profitable, with an operating margin of 42.1% against 11.6%.
Where the money goes: CRMD and HROW
CorMedix (CRMD) · Q2 2026
CorMedix, Q2 2026: revenue $102M (+156% year over year), operating margin 42.1%, net earnings $26.0M, operating cash flow $86.2M. The chart follows the revenue to costs, profit and cash.
Harrow (HROW) · Q3 2026
Harrow, Q3 2026: revenue $99.3M (+39% year over year), operating margin 11.6%, net earnings $9.8M. The chart follows the revenue to costs, profit and cash.
| CorMedix (CRMD) | Harrow (HROW) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $102M | $99.3M |
| Revenue growth, Y/Y | +156% | +39% |
| Gross margin | 75.7% | 75.4% |
| Operating margin | 42.1% | 11.6% |
| Net earnings | $26.0M | $9.8M |
| Net margin | 25.5% | 9.8% |
| Operating cash flow | $86.2M | — |
| Free cash flow | $85.7M | — |
Where the revenue comes from
CorMedix
- Product sales, net: $94.3M (93%)
- Contract revenue: $5.0M (5%)
- Grant income: $2.6M (3%)
Questions
Which is bigger, CorMedix or Harrow?
CorMedix is the larger company: $102M of revenue in its latest quarter (Q2 2026) against $99.3M for Harrow (Q3 2026).
Is CorMedix or Harrow growing faster?
CorMedix is growing faster (+156% against +39% a year earlier).
Which is more profitable, CorMedix or Harrow?
CorMedix is more profitable, with an operating margin of 42.1% against 11.6%.
More: CorMedix earnings · how CorMedix makes money · Harrow earnings · how Harrow makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 8-K filed Nov 9, 2026). Fiscal quarters can end on different dates. Not investment advice.